JP2017503009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503009A5 JP2017503009A5 JP2016558545A JP2016558545A JP2017503009A5 JP 2017503009 A5 JP2017503009 A5 JP 2017503009A5 JP 2016558545 A JP2016558545 A JP 2016558545A JP 2016558545 A JP2016558545 A JP 2016558545A JP 2017503009 A5 JP2017503009 A5 JP 2017503009A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- antibody
- nhc
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229940125644 antibody drug Drugs 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- -1 cyano, sulfonyl Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102100020998 Aspartate beta-hydroxylase domain-containing protein 1 Human genes 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims 1
- 102100024220 CD180 antigen Human genes 0.000 claims 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 102100020743 Dipeptidase 1 Human genes 0.000 claims 1
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims 1
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims 1
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims 1
- 101000783987 Homo sapiens Aspartate beta-hydroxylase domain-containing protein 1 Proteins 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims 1
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101100499854 Homo sapiens DPEP1 gene Proteins 0.000 claims 1
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims 1
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims 1
- 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 claims 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 1
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000829779 Homo sapiens Probable G-protein coupled receptor 19 Proteins 0.000 claims 1
- 101000825475 Homo sapiens Protein shisa-2 homolog Proteins 0.000 claims 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims 1
- 101000853730 Homo sapiens RING finger and transmembrane domain-containing protein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims 1
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims 1
- 101000834937 Homo sapiens Tomoregulin-1 Proteins 0.000 claims 1
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims 1
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 1
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037603 P2X purinoceptor 5 Human genes 0.000 claims 1
- 101710189969 P2X purinoceptor 5 Proteins 0.000 claims 1
- 102100023417 Probable G-protein coupled receptor 19 Human genes 0.000 claims 1
- 102100022938 Protein shisa-2 homolog Human genes 0.000 claims 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims 1
- 102100035928 RING finger and transmembrane domain-containing protein 2 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims 1
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims 1
- 102100026159 Tomoregulin-1 Human genes 0.000 claims 1
- 102100026160 Tomoregulin-2 Human genes 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 102000003425 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 C*NC([C@](*)*(C1)*1C(S(C)=C)=O)=O Chemical compound C*NC([C@](*)*(C1)*1C(S(C)=C)=O)=O 0.000 description 3
- XYYXDARQOHWBPO-UHFFFAOYSA-N Cc1nnc(C)[nH]1 Chemical compound Cc1nnc(C)[nH]1 XYYXDARQOHWBPO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916675P | 2013-12-16 | 2013-12-16 | |
| US61/916,675 | 2013-12-16 | ||
| PCT/US2014/070493 WO2015095124A1 (en) | 2013-12-16 | 2014-12-16 | Peptidomimetic compounds and antibody-drug conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019233580A Division JP2020045370A (ja) | 2013-12-16 | 2019-12-24 | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503009A JP2017503009A (ja) | 2017-01-26 |
| JP2017503009A5 true JP2017503009A5 (cg-RX-API-DMAC7.html) | 2018-02-08 |
| JP6681838B2 JP6681838B2 (ja) | 2020-04-15 |
Family
ID=52273598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558545A Active JP6681838B2 (ja) | 2013-12-16 | 2014-12-16 | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
| JP2019233580A Pending JP2020045370A (ja) | 2013-12-16 | 2019-12-24 | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019233580A Pending JP2020045370A (ja) | 2013-12-16 | 2019-12-24 | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10533058B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3082872B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6681838B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102337414B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105848685B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016014126B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2931798C (cg-RX-API-DMAC7.html) |
| EA (1) | EA033456B1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1222577A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX381017B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ720743A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015095124A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201603697B (cg-RX-API-DMAC7.html) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| BR112012026801B8 (pt) | 2010-04-15 | 2021-05-25 | Medimmune Ltd | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| EA027971B1 (ru) | 2011-09-20 | 2017-09-29 | Медимьюн Лимитед | Пирролбензодиазепины |
| MX375987B (es) | 2011-10-14 | 2025-03-07 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| JP6393617B2 (ja) | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| CA2850264C (en) | 2011-10-14 | 2019-11-05 | Spirogen Sarl | Pyrrolobenzodiazepines |
| AU2013328673B2 (en) | 2012-10-12 | 2017-07-13 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| EP3470086B1 (en) | 2012-10-12 | 2020-11-25 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
| EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AR096287A1 (es) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados |
| MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10533058B2 (en) * | 2013-12-16 | 2020-01-14 | Genentech Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
| CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201701623UA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
| PE20170670A1 (es) | 2014-09-12 | 2017-06-06 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3226908A1 (en) * | 2014-12-03 | 2017-10-11 | F.Hoffmann-La Roche Ag | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
| JP6752204B2 (ja) * | 2014-12-03 | 2020-09-09 | ジェネンテック， インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
| WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
| TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
| GB201513607D0 (en) * | 2015-07-31 | 2015-09-16 | Feingold Jay M | Pyrrolobenzodiazepine-antibody conjugates |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| US10143695B2 (en) | 2016-05-18 | 2018-12-04 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法 |
| WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| TWI760344B (zh) | 2016-06-24 | 2022-04-11 | 美商梅爾莎納醫療公司 | 吡咯並苯並二氮呯類和彼等之共軛物類 |
| CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| EP3544636B1 (en) | 2017-02-08 | 2021-03-31 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CA3059519C (en) * | 2017-04-18 | 2021-03-23 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| MX384245B (es) | 2017-08-18 | 2025-03-14 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| IL273471B2 (en) | 2017-09-29 | 2023-09-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
| US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| TW202031298A (zh) | 2018-11-14 | 2020-09-01 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體－吡咯并苯二氮呯衍生物結合物 |
| MA53455B1 (fr) | 2018-11-20 | 2022-11-30 | Regeneron Pharma | Dérivés de bis-octahydrophénanthrène carboxamide et leurs conjugués protéiques destinés à être utilisés en tant qu'agonistes de lxr |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| KR102362284B1 (ko) * | 2019-01-23 | 2022-02-11 | 앱티스 주식회사 | 항체-페이로드 컨쥬게이트 제조용 화합물, 이의 용도 |
| KR20210127714A (ko) * | 2019-03-07 | 2021-10-22 | 에이비엘바이오 주식회사 | 항체-약물 접합체 및 이의 용도 |
| AU2020242747B2 (en) | 2019-03-15 | 2025-09-18 | Medimmune Limited | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| WO2020196475A1 (ja) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| TWI841715B (zh) | 2019-03-27 | 2024-05-11 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途 |
| WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
| MX2023000888A (es) | 2020-07-21 | 2023-02-22 | Genentech Inc | Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos. |
| CA3191395A1 (en) | 2020-09-02 | 2022-03-10 | Daiichi Sankyo Company, Limited | Novel endo-.beta.-n-acetylglucosaminidase |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023100829A1 (ja) | 2021-11-30 | 2023-06-08 | 第一三共株式会社 | プロテアーゼ分解性マスク抗体 |
| AR128331A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpos y métodos de estos |
| AR128330A1 (es) | 2022-01-26 | 2024-04-17 | Genentech Inc | Inductores químicos de degradación conjugados con anticuerpo y métodos de estos |
| WO2023153442A1 (ja) | 2022-02-09 | 2023-08-17 | 第一三共株式会社 | 環境応答性マスク抗体及びその利用 |
| TW202346322A (zh) | 2022-03-02 | 2023-12-01 | 日商第一三共股份有限公司 | 含Ｆｃ分子之製造方法 |
| EP4637833A2 (en) | 2022-12-23 | 2025-10-29 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| WO2025096716A1 (en) | 2023-11-01 | 2025-05-08 | Incyte Corporation | Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof |
| KR102786374B1 (ko) | 2024-11-08 | 2025-03-24 | 노인균 | 조명 매립이 가능한 걸레받이 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CN104447992A (zh) | 2004-09-23 | 2015-03-25 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| AU2011239507B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR101839163B1 (ko) | 2010-06-08 | 2018-03-15 | 제넨테크, 인크. | 시스테인 조작된 항체 및 접합체 |
| ES2641090T3 (es) * | 2011-03-29 | 2017-11-07 | Covestro Deutschland Ag | Uso de una preparación acuosa para el revestimiento de superficies de madera para lograr un efecto de tacto natural |
| EA027971B1 (ru) | 2011-09-20 | 2017-09-29 | Медимьюн Лимитед | Пирролбензодиазепины |
| US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6393617B2 (ja) * | 2011-10-14 | 2018-09-19 | シアトル ジェネティクス，インコーポレーテッド | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| EP2751111B1 (en) * | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| AR091098A1 (es) * | 2012-05-21 | 2015-01-14 | Genentech Inc | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO |
| WO2014057120A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| AR096287A1 (es) | 2013-03-13 | 2015-12-23 | Spirogen Sàrl | Pirrolobenzodiacepinas y conjugados |
| WO2014193722A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| TWI632157B (zh) | 2013-05-31 | 2018-08-11 | 建南德克公司 | 抗壁磷壁酸抗體（ａｎｔｉ－ｗａｌｌ ｔｅｉｃｈｏｉｃ ａｃｉｄ ａｎｔｉｂｏｄｉｅｓ）及結合物 |
| US9803002B2 (en) | 2013-05-31 | 2017-10-31 | Genentench, Inc. | Anti-wall teichoic antibodies and conjugates |
| MX369022B (es) | 2013-05-31 | 2019-10-25 | Genentech Inc | Anticuerpos anti-ácido teicoico de la pared celular y conjugados. |
| MX2016001862A (es) | 2013-08-12 | 2016-08-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. |
| BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
| US10533058B2 (en) * | 2013-12-16 | 2020-01-14 | Genentech Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| PE20170670A1 (es) | 2014-09-12 | 2017-06-06 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| EP3235820A1 (en) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| EP3226908A1 (en) | 2014-12-03 | 2017-10-11 | F.Hoffmann-La Roche Ag | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
| BR112017011325A2 (pt) | 2014-12-03 | 2020-07-21 | Genentech, Inc. | ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga? |
| JP6752204B2 (ja) | 2014-12-03 | 2020-09-09 | ジェネンテック， インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
-
2014
- 2014-12-16 US US15/104,388 patent/US10533058B2/en active Active
- 2014-12-16 BR BR112016014126-1A patent/BR112016014126B1/pt not_active IP Right Cessation
- 2014-12-16 NZ NZ720743A patent/NZ720743A/en not_active IP Right Cessation
- 2014-12-16 JP JP2016558545A patent/JP6681838B2/ja active Active
- 2014-12-16 CN CN201480068353.3A patent/CN105848685B/zh active Active
- 2014-12-16 KR KR1020167018766A patent/KR102337414B1/ko not_active Expired - Fee Related
- 2014-12-16 CA CA2931798A patent/CA2931798C/en active Active
- 2014-12-16 EP EP14821453.9A patent/EP3082872B1/en active Active
- 2014-12-16 WO PCT/US2014/070493 patent/WO2015095124A1/en not_active Ceased
- 2014-12-16 HK HK16110846.7A patent/HK1222577A1/zh unknown
- 2014-12-16 KR KR1020217030522A patent/KR102405762B1/ko active Active
- 2014-12-16 EA EA201691059A patent/EA033456B1/ru not_active IP Right Cessation
- 2014-12-16 MX MX2016007851A patent/MX381017B/es unknown
-
2016
- 2016-05-31 ZA ZA201603697A patent/ZA201603697B/en unknown
-
2019
- 2019-11-26 US US16/696,455 patent/US11692043B2/en active Active
- 2019-12-24 JP JP2019233580A patent/JP2020045370A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503009A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503011A5 (cg-RX-API-DMAC7.html) | ||
| JP2017504606A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512211A5 (cg-RX-API-DMAC7.html) | ||
| JP2014534199A5 (cg-RX-API-DMAC7.html) | ||
| TR201902494T4 (tr) | Pirrolobenzodiazepinler ve onların konjugatları. | |
| Ojima et al. | Tumor-specific novel taxoid− monoclonal antibody conjugates | |
| JP2024012491A (ja) | 抗体ｐｒｏｔａｃコンジュゲート | |
| JP2015533141A5 (cg-RX-API-DMAC7.html) | ||
| ME02055B (me) | Pirolobenzodiazepini i njihovi konjugati | |
| JP2016539915A5 (cg-RX-API-DMAC7.html) | ||
| JP6445519B2 (ja) | ピロロベンゾジアゼピン及びそのコンジュゲート | |
| Vineberg et al. | Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid–camptothecin combination chemotherapy | |
| Lee et al. | Conjugated chitosan as a novel platform for oral delivery of paclitaxel | |
| JP2013542958A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516860A5 (cg-RX-API-DMAC7.html) | ||
| RU2018127242A (ru) | Пирролобензодиазепиновые конъюгаты | |
| JP2018162257A5 (cg-RX-API-DMAC7.html) | ||
| HRP20130953T1 (hr) | Pirolobenzodiazepini i njihovi konjugati | |
| Hamann et al. | An anti-MUC1 antibody− calicheamicin conjugate for treatment of solid tumors. choice of linker and overcoming drug resistance | |
| RU2016101244A (ru) | Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры | |
| JP2014528466A5 (cg-RX-API-DMAC7.html) | ||
| JP2014523412A5 (cg-RX-API-DMAC7.html) | ||
| JP2015528818A5 (cg-RX-API-DMAC7.html) | ||
| RU2019113990A (ru) | Нелинейные саморасщепляющиеся линкеры и их конъюгаты |